

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSE ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA. INITIAL PUBLIC OFFER OF EQUITY SHARES ON THE SME PLATFORM OF NSE ("NSE EMERGE") IN COMPLIANCE WITH CHAPTER IX OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED



(Please scan this QR Code to view the Prospectus)



**Accretion®**  
Pharmaceuticals Limited

**ACCRETION PHARMACEUTICALS LIMITED**  
Corporate Identification Number (CIN): U21004GJ2023PLC146545

Accretion Pharmaceuticals was incorporated in the year 2012, our Promoters Mr. Harshad Nanubhai Rathod, Mr. Vivek Ashok Kumar Patel, Mr. Mayur Popatlal Sojitra and Mr. Hardik Mukundbhai Prajapati, came together to establish a pharmaceutical manufacturing unit, with vision to provide health care products that match international quality standards at competitive price. Thus, the foundation of "Accretion Pharmaceuticals" was laid down, which was started as a Partnership Firm under the Partnership Act, 1932 ("Partnership Act") in the name and style of "M/s Accretion Pharmaceuticals", pursuant to a deed of partnership dated December 16, 2012. Our manufacturing facility which is currently located at 28 & 29 Xcelon Ind Park 1, B/H, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat 382213, commenced its manufacturing operations in year 2014. Thereafter, pursuant to a resolution passed by the partners of M/s Accretion Pharmaceuticals on October 16, 2023, the Partnership Firm was converted into a Limited Company under Part I (Chapter XXI) of the Companies Act, 2013 in the name of "Accretion Pharmaceuticals Limited" and a certificate of incorporation dated November 29, 2023 was issued by the Registrar of Companies, Central Registration Centre, for and on behalf of the jurisdictional Registrar of Companies.

**Regd. Office :** 29 Xcelon Ind Park 1, B/H, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat, India, 382213;  
**Tel No.:** +91-97148 82929; **E-mail:** [compliance@accretionpharma.com](mailto:compliance@accretionpharma.com); **Website:** <http://www.accretionpharma.com>  
**Contact Person:** Ms. Bhavika Dhaval Makadia, Company Secretary & Compliance Officer •

**THE PROMOTER OF THE COMPANY ARE MR. HARSHAD NANUBHAI RATHOD, MR. VIVEK ASHOK KUMAR PATEL, MR. MAYUR POPATLAL SOJITRA, AND MR. HARDIK MUKUNDBHAI PRAJAPATI**

**THE ISSUE**

INITIAL PUBLIC OFFER OF 29,46,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH (THE "EQUITY SHARES") OF ACCRETION PHARMACEUTICALS LIMITED ("OUR COMPANY" OR "ACCRETION" OR "THE ISSUER") AT AN ISSUE PRICE OF RS. [•] PER EQUITY SHARE FOR CASH, AGGREGATING UP TO RS. [•] LAKHS ("PUBLIC ISSUE") OUT OF WHICH 1,47,600 EQUITY SHARES OF FACE VALUE OF RS. 10 EACH, AT AN ISSUE PRICE OF RS. [•] PER EQUITY SHARE FOR CASH, AGGREGATING RS. [•] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE PUBLIC ISSUE LESS MARKET MAKER RESERVATION PORTION I.E., ISSUE OF UPTO 27,98,400 EQUITY SHARES OF FACE VALUE OF RS. 10 EACH, AT AN ISSUE PRICE OF RS. [•] PER EQUITY SHARE FOR CASH, AGGREGATING UPTO RS. [•] LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE PUBLIC ISSUE AND NET ISSUE WILL CONSTITUTE 26.50 % AND 25.17% RESPECTIVELY OF THE POST-ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY

**PRICE BAND: RS. 96.00 to RS. 101.00 PER EQUITY SHARE OF FACE VALUE OF RS. 10.00 EACH**

ISSUE PROGRAMME	ANCHOR BID/ISSUE OPENS ON: TUESDAY, MAY 13, 2025	ISSUE OPENS ON: WEDNESDAY, MAY 14, 2025	ISSUE CLOSES ON: FRIDAY, MAY 16, 2025
-----------------	--	---	---------------------------------------

**NOTICE TO INVESTORS:  
CORRIGENDUM TO THE RED HERRING PROSPECTUS DATED MAY 06, 2025 (THE "CORRIGENDUM")**

This Corrigendum is with reference to the Red Herring Prospectus dated May 06, 2025, filed with Registrar of Companies, Ahmedabad and the Pre-Issue and Price Band Advertisement each dated May 06, 2025 published on May 07, 2025 ("Price Issue Advertisement") in all editions of Financial Express (all Editions), Jansatta (all Editions) and Financial Express Gujarati ("Gujarati Edition").

The attention of investor is drawn to the following  
Below mentioned procedure outlining the process for allotment from the closure of the issue, is inserted above the heading "Method of allotment as may be prescribed by SEBI from time to time" appearing on page no. 386 under the chapter "ISSUE PROCEDURE" of the Red Herring Prospectus:

**Basis of Allotment**

The Allotment of Equity Shares to Bidders other than Retail Individual Investors may be on proportionate basis. No Retail Individual Investor will be Allotted less than the minimum Bid Lot subject to availability of shares in Retail Individual Investor Category and the remaining available shares, if any will be Allotted on a proportionate basis. The Issuer is required to receive a minimum subscription of 90% of the Issue. However, in case the Issue is in the nature of Offer for Sale only, then minimum subscription may not be applicable.

**Flow of Events from the closure of bidding period (T DAY) Till Allotment:**

- On T Day, RTA to validate the electronic bid details with the depository records and also reconcile the final certificates received from the Sponsor Bank for UPI process and the SCSBs for ASBA and Syndicate ASBA process with the electronic bid details.
- RTA identifies cases with mismatch of account number as per bid file/ Final Certificate and as per applicant's bank account linked to depository demat account and seek clarification from SCSBs to identify the applications with third party account for rejection.
- Third party confirmation of applications to be completed by SCSBs on T+ 1 day.
- RTA prepares the list of final rejections and circulate the rejections list with BRLM/ Company for their review/comments.
- Post rejection, the RTA submits the basis of allotment with the Designated Stock Exchange (DSE).
- The Designated Stock Exchange (DSE), post verification approves the basis and generates drawal of lots wherever applicable, through a random number generation software.
- The RTA uploads the drawal numbers in their system and generates the final list of allottees as per process mentioned below:

**Process for generating list of allottees: -**


- Instruction is given by RTA in their Software System to reverse category wise all the application numbers in the ascending order and generate the bucket/batch as per the allotment ratio. For example, if the application number is 78654321 then system reverses it to 12345687 and if the ratio of allottees to applicants in a category is 2:7 then the system will create lots of 7. If the drawal of lots provided by Designated Stock Exchange (DSE) is 3 and 5 then the system will pick every 3rd and 5th Application in each of the lot of the category and these applications will be allotted the shares in that category.
- In categories where there is proportionate allotment, the Registrar will prepare the proportionate working based on the over subscription times.
- In categories where there is undersubscription, the Registrar will do full allotment for all valid applications.
- On the basis of the above, the RTA will work out the allottees, partial allottees and non-allottees, prepare the fund transfer letters and advice the SCSBs to debit or unblock the respective accounts.

The Red Herring Prospectus shall be read in conjunction with this Corrigendum. The information in this Corrigendum supersedes the information in the Red Herring Prospectus to the extent inconsistent with the information in the Red Herring Prospectus.

Relevant changes shall be reflected in the Prospectus when registered with the RoC and filed with SEBI and NSE.

Unless otherwise specified, all capitalised terms used herein shall have the same meaning ascribed to such terms in the Red Herring Prospectus.

**BOOK RUNNING LEAD MANAGER TO THE ISSUE**



**JAWA CAPITAL SERVICES**

**Jawa Capital Services Private Limited**  
CIN: U74140DL2005PTC137680  
Plot No. 93, F/F, Pocket-2, Near DAV School, Jasola, Delhi-110025  
**Tel:** +91-11-47366600; **E-mail:** [mdbd@jawacapital.in](mailto:mdbd@jawacapital.in)  
**Investor Grievance Email:** [investorsrelations@jawacapital.in](mailto:investorsrelations@jawacapital.in) **Website:** [www.jawacapital.in](http://www.jawacapital.in)  
**Contact Person:** Mr. Taranveer Singh/ Mr. Sajal Gupta  
**SEBI Registration No.:** MB/INM000012777

**REGISTRAR TO THE ISSUE**



**KFINTeCH**  
EXPERIENCE TRANSFORMATION

**KFIN TECHNOLOGIES LIMITED**  
**Address:** Selenium Tower-B, Plot 31 & 32, Gachibowli, Financial District, Nanakramguda, Serilingampally, Hyderabad – 500 032,  
**Tel:** +91 40 6716 2222; **Toll Free No.:** 1800 309 4001;  
**Email Id:** [apl ipo@kfintech.com](mailto:apl ipo@kfintech.com) **Investor Grievance Email Id:** [einward.ris@kfintech.com](mailto:einward.ris@kfintech.com)  
**Website:** [www.kfintech.com](http://www.kfintech.com)  
**Contact Person:** Mr. M Murali Krishna **SEBI Registration No.:** INR000000221

**COMPANY SECRETARY AND COMPLIANCE OFFICER**



**Accretion®**  
Pharmaceuticals Limited

**Ms. Bhavika Dhaval Makadia**  
**ACCRETION PHARMACEUTICALS LIMITED**  
29 Xcelon Ind Park 1, B/h, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat, India, 382213  
**Tel No.:** +91-97148 82929 **E-mail:** [compliance@accretionpharma.com](mailto:compliance@accretionpharma.com)  
**Website:** <http://www.accretionpharma.com>

Investors can contact the Compliance Officer or the Registrar in case of any pre-Issue or post-Issue related problems, such as non-receipt of letters of allocation, credit of allotted Equity Shares in the respective beneficiary accounts or unblocking of ASBA accounts etc.

**For ACCRETION PHARMACEUTICALS LIMITED**  
On behalf of the Board of Directors  
Sd/-  
**(VIVEK ASHOK KUMAR PATEL)**  
Managing Director  
DIN: 09130357

**ACCRETION PHARMACEUTICALS LIMITED** is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make initial public offering of its Equity Shares and has filed the Red Herring Prospectus with the Registrar of Companies, Ahmedabad. The Red Herring Prospectus is expected to be available on the website of the SEBI at [www.sebi.gov.in](http://www.sebi.gov.in) and the website of the Book Running Lead Manager to the Issue at [www.jawacapital.in](http://www.jawacapital.in) and website of the NSE Limited at [www.nseindia.com](http://www.nseindia.com) and website of Issuer Company at [www.accretionpharma.com](http://www.accretionpharma.com). Investors should note that investment in Equity Shares involves high degree of risks. For details, investors should refer to and rely on the Red Herring Prospectus, including the section titled "Risk Factors" on page 33 of the Red Herring Prospectus. Potential Bidders should not rely on the DRHP filed with NSE for making any investment decision instead investors shall rely on RHP filed with the RoC.

The Equity Shares have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act") or any state securities law in United States and may not be offered or sold within the United States (as defined in Regulation S under the Securities Act) or to, or for the account benefit of "U. S. Person" (as defined in the Regulations under the Securities Act), except pursuant to an exemption from, or in a transaction not subject to the registration requirements of the Securities Act.